LODICAND Olaszország - olasz - AIFA (Agenzia Italiana del Farmaco)

lodicand

bruno farmaceutici s.p.a. - candesartan e amlodipina - candesartan e amlodipina

ROSULOD Olaszország - olasz - AIFA (Agenzia Italiana del Farmaco)

rosulod

zentiva k.s. - rosuvastatina ed amlodipina - rosuvastatina ed amlodipina

CAMLAD Olaszország - olasz - AIFA (Agenzia Italiana del Farmaco)

camlad

adamed s.r.l. - candesartan e amlodipina - candesartan e amlodipina

DEFUCITAN Olaszország - olasz - AIFA (Agenzia Italiana del Farmaco)

defucitan

aflofarm farmacja polska spolka z ograniczona odpowiedzialnoscia - cytisine - cytisine

Bevespi Aerosphere Európai Unió - olasz - EMA (European Medicines Agency)

bevespi aerosphere

astrazeneca ab - glycopyrronium, formoterol fumarate dihydrate - malattia polmonare, ostruttiva cronica - formoterolo e glycopyrronium bromuro - bevespi aerosphere è indicato come un broncodilatatore di mantenimento di trattamento per alleviare i sintomi in pazienti adulti con malattia polmonare ostruttiva cronica (bpco).

Trixeo Aerosphere Európai Unió - olasz - EMA (European Medicines Agency)

trixeo aerosphere

astrazeneca ab - formoterol fumarate dihydrate, glycopyrronium bromide, budesonide - malattia polmonare, ostruttiva cronica - farmaci per le malattie respiratorie ostruttive, - trixeo aerosphere is indicated as a maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (copd) who are not adequately treated by a combination of an inhaled corticosteroid and a long acting beta2 agonist or combination of a long-acting beta2 agonist and a long acting muscarinic antagonist.

Riltrava Aerosphere Európai Unió - olasz - EMA (European Medicines Agency)

riltrava aerosphere

astrazeneca ab - budesonide, formoterol fumarate dihydrate, glycopyrronium bromide - malattia polmonare, ostruttiva cronica - farmaci per le malattie respiratorie ostruttive, - riltrava aerosphere is indicated as a maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (copd) who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting beta2 agonist or combination of a long-acting beta2 agonist and a long-acting muscarinic antagonist (for effects on symptoms control and prevention of exacerbations see section 5.